High Tide Reports Record-Breaking Third Quarter 2026 Financial Results

High Tide reported record fiscal Q3 2026 revenue of C$198.8M, up 33% year over year and 11% sequentially, alongside record adjusted EBITDA of C$16.2M (+53%) and an 8.2% margin, its highest in 12 quarters. Net income reached C$12.7M versus C$0.8M a year earlier, while free cash flow was C$7.0M and cash rose sequentially to C$47.1M. Canna Cabana expanded its market share to 14% outside British Columbia, while German medical-cannabis distributor Remexian delivered C$38.2M in revenue and distributed a record 10.2 tonnes; management reiterated expansion targets of more than 20 Canadian store openings in 2026 and over 350 long term.

Analysis

HITI’s investable change is not revenue scale but evidence that the retail model is beginning to convert incremental sales into operating profit while its German distribution operation diversifies the earnings base. The key valuation question is whether the current EBITDA step-up is repeatable after acquisition costs and working-capital investment, rather than whether the reported net-income headline is sustainable; adjusted earnings remain much smaller. If repeatable, sustained high-single-digit EBITDA margins would justify a rerating versus Canadian cannabis retailers that remain trapped in price competition and fixed-cost deleveraging.

The most material near-term catalyst is management’s ability to demonstrate positive same-store sales and stable gross margin while opening locations. A discount/loyalty model can widen local share, but it also creates a ceiling on margin unless private-label penetration rises materially from its current low base; that is the 6-18 month margin lever, not store count alone. Germany is potentially higher quality growth, but rapid volume expansion also raises receivables, inventory and regulatory-reimbursement risk; monitor cash conversion rather than shipment volumes.

The new BMO facility lowers liquidity risk and can accelerate consolidation of weaker independents, which is a competitive negative for peers such as SNDL and Fire & Flower’s residual competitive set, but leverage-funded M&A would dilute the clean free-cash-flow narrative. U.S. reform optionality should receive little base-case value: exchange eligibility and federal enforcement/listing rules, not a DEA process alone, determine whether HITI can deploy capital into U.S. THC retail. NDAQ’s direct earnings exposure is negligible, though a clarified exchange policy could create a sentiment catalyst across listed cannabis equities.

Key Decisions for Investors

• Initiate a 1-3 month tactical long HITI only on post-call confirmation that FY2026 free cash flow remains positive after growth capex and that German working-capital needs are contained; target a 15-25% rerating from earnings multiple expansion, with a 10% stop or exit on renewed negative same-store sales.
• Use a 6-12 month pair: long HITI / short SNDL, sized beta-neutral. HITI’s advantage is operating-cost leverage and a scalable German channel; invalidate if HITI’s EBITDA margin falls below 7% for two quarters or SNDL demonstrates superior FCF conversion from its retail portfolio.
• Do not underwrite the reported net-income run rate. Require adjusted net income, operating cash flow after working-capital changes, and trailing-12-month FCF to improve together before increasing position size; a growing receivables/inventory balance alongside German volume growth is a sell/trim signal.
• Set an event alert around formal Nasdaq (NDAQ) and TSXV guidance on U.S. cannabis exposure. A permissive policy would make HITI a higher-quality listed optionality vehicle; absent explicit exchange-rule change, assign no material value to U.S. expansion claims.